BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cipla
Julphar
Merck
Harvard Business School
Moodys
Boehringer Ingelheim
Mallinckrodt
Cantor Fitzgerald
Chinese Patent Office

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 088292

« Back to Dashboard

NDA 088292 describes IMIPRAMINE HYDROCHLORIDE, which is a drug marketed by Novartis, Leading Pharma Llc, Lederle, Lupin Ltd, Mallinckrodt Inc, Oxford Pharms, Par Pharm, Roxane, Sandoz, Sun Pharm Industries, Teva, Usl Pharma, Vangard, Watson Labs, and West Ward, and is included in thirty-six NDAs. It is available from nineteen suppliers. Additional details are available on the IMIPRAMINE HYDROCHLORIDE profile page.

The generic ingredient in IMIPRAMINE HYDROCHLORIDE is imipramine hydrochloride. There are thirty-four drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the imipramine hydrochloride profile page.
Summary for 088292
Tradename:IMIPRAMINE HYDROCHLORIDE
Applicant:Par Pharm
Ingredient:imipramine hydrochloride
Patents:0
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details
Pharmacology for NDA: 088292
Suppliers and Packaging for NDA: 088292
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IMIPRAMINE HYDROCHLORIDE imipramine hydrochloride TABLET;ORAL 088292 ANDA KAISER FOUNDATION HOSPITALS 0179-0118 0179-0118-70 30 TABLET in 1 BOX, UNIT-DOSE (0179-0118-70)
IMIPRAMINE HYDROCHLORIDE imipramine hydrochloride TABLET;ORAL 088292 ANDA Par Pharmaceutical, Inc. 49884-054 49884-054-01 100 TABLET in 1 BOTTLE (49884-054-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Oct 21, 1983TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Julphar
Fuji
Fish and Richardson
McKesson
Deloitte
AstraZeneca
Cerilliant
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot